Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/08/2859599/0/en/Olema-Oncology-to-Participate-in-Canaccord-Genuity-2024-Horizons-in-Oncology-Virtual-Conference.html
https://www.globenewswire.com/news-release/2024/04/02/2856485/0/en/Olema-Oncology-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com//news-release/2024/03/11/2844138/0/en/Olema-Oncology-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Corporate-Update.html
https://www.globenewswire.com//news-release/2024/03/06/2841269/0/en/Olema-Oncology-Announces-Publication-of-Data-Highlighting-Palazestrant-s-Ability-to-Inhibit-Wild-Type-and-Mutant-ER-Breast-Cancer-Both-as-Monotherapy-and-in-Combination-with-CDK4-6.html
https://www.globenewswire.com//news-release/2024/03/04/2839999/0/en/Olema-Oncology-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com//news-release/2024/02/06/2824168/0/en/Olema-Oncology-to-Participate-in-Upcoming-Investor-Conferences.html
https://www.globenewswire.com//news-release/2024/02/02/2823067/0/en/Olema-Oncology-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com//news-release/2024/01/08/2805428/0/en/Olema-Oncology-Nominates-OP-3136-an-Orally-Bioavailable-KAT6-Inhibitor-as-a-Development-Candidate.html
https://www.globenewswire.com//news-release/2024/01/02/2802916/0/en/Olema-Oncology-to-Present-at-42nd-Annual-J-P-Morgan-Healthcare-Conference.html
https://www.globenewswire.com/news-release/2023/12/05/2791260/0/en/Olema-Oncology-Announces-Palazestrant-Demonstrates-Attractive-Combinability-with-CDK4-6-Inhibitors-Ribociclib-and-Palbociclib-in-Phase-1b-2-Studies.html